Developing antisense therapeutics for multiple myeloma
Source abstract
Abstract
Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron, Immunity, Current Biology, AJHG, and the Trends Journals.
Only a short abstract or summary was supplied by the source.
Source: openalex_inverted_index · Quality: short
Research context
OpenAlex topics: Multiple Myeloma Research and Treatments · Cancer Research and Treatment · Cancer and biochemical research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Multiple myeloma10.1016/S0140-6736(09)60221-X ↗
2. Diagnostic criteria of multiple myeloma10.1016/S0889-8588(18)30348-4 ↗
3. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma10.1111/ijlh.12504 ↗
4. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols10.1111/j.1365-2141.2008.07547.x ↗
5. Review of 1027 patients with newly diagnosed multiple myeloma10.4065/78.1.21 ↗
6. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma10.1016/S1470-2045(14)70442-5 ↗
7. A long-term study of prognosis in monoclonal gammopathy of undetermined significance10.1056/NEJMoa01133202 ↗
8. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study10.1016/S0140-6736(10)60482-5 ↗
9. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice10.1080/10428194.2019.1620948 ↗
10. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma10.1056/NEJMoa070389 ↗
11. Extramedullary disease in multiple myeloma: a systematic literature review10.1038/s41408-022-00643-3 ↗
12. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome10.3324/haematol.2019.219295 ↗
13. Lee · 1993
14. Paraprotein-Related Kidney Disease: Attack of the Killer M Proteins10.2215/CJN.02960316 ↗
15. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL)10.1016/j.exphem.2004.03.015 ↗
16. Osteoclasts: what do they do and how do they do it?10.2353/ajpath.2007.060834 ↗
17. Cancer-related hypercalcemia
18. Multiple myeloma: an overview of management
19. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives10.21037/atm.2019.01.42 ↗
20. Daratumumab: First Global Approval10.1007/s40265-015-0536-1 ↗
21. Isatuximab: First Approval10.1007/s40265-020-01311-1 ↗
22. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment10.1177/2040620716652862 ↗
23. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study10.1016/S1470-2045(19)30788-0 ↗
24. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study10.1038/s41408-020-00369-0 ↗
25. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network10.1093/annonc/mdn796 ↗
26. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains10.1038/ki.2008.108 ↗
27. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide10.1038/leu.2012.119 ↗
28. Identification of a primary target of thalidomide teratogenicity10.1126/science.1177319 ↗
29. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM)10.1038/sj.thj.6200175 ↗
30. Thalidomide for the treatment of multiple myeloma10.1111/j.1741-4520.2004.00025.x ↗
31. Thalidomide in multiple myeloma10.2174/138920106779116919 ↗
32. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma10.1056/NEJMoa1817249 ↗
33. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma10.1182/blood-2005-07-2817 ↗
34. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum10.1101/gad.12.7.982 ↗
35. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state10.1128/MCB.21.4.1249-1259.2001 ↗
36. Perk is essential for translational regulation and cell survival during the unfolded protein response10.1016/S1097-2765(00)80330-5 ↗
37. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival10.1016/S1097-2765(01)00264-7 ↗
38. Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity10.1097/PPO.0000000000000155 ↗
39. Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects10.1155/2016/3850839 ↗
40. Engineering CAR-T cells: Design concepts10.1016/j.it.2015.06.004 ↗
41. Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers10.3390/cancers12051075 ↗
42. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells10.1158/1078-0432.CCR-15-0489 ↗
43. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma10.1158/0008-5472.CAN-15-0457 ↗
44. NCCN Guidelines® Insights: Multiple Myeloma, Version 1.202510.6004/jnccn.2025.0023 ↗
45. Proteasome inhibitors in cancer therapy10.1038/nrclinonc.2016.206 ↗
46. Lenalidomide induces degradation of IKZF1 and IKZF310.4161/21624011.2014.941742 ↗
47. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma10.1056/NEJMoa1506348 ↗
48. Teclistamab in Relapsed or Refractory Multiple Myeloma10.1056/NEJMoa2203478 ↗
49. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma10.1056/NEJMoa2024850 ↗
50. Multiple myeloma10.1056/NEJMra1011442 ↗
51. Treatment of myeloma bone disease: When, how often, and for how long?10.1016/j.jbo.2025.100680 ↗
52. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma10.1038/s41375-019-0542-5 ↗
53. Metazoan MicroRNAs10.1016/j.cell.2018.03.006 ↗
54. Antisense oligonucleotides-based approaches for the treatment of multiple myeloma10.1016/j.ijbiomac.2024.139186 ↗
55. Antisense Oligonucleotides: A Unique Treatment Approach10.1007/s13312-020-1736-7 ↗
56. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development10.3390/jcm9062004 ↗
57. Phosphorothioates, essential components of therapeutic oligonucleotides10.1089/nat.2014.0506 ↗
58. The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytogenetics10.1038/sj.ejhg.5201226 ↗
59. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation10.1089/oli.1.1996.6.267 ↗
60. Design of antisense oligonucleotides stabilized by locked nucleic acids10.1093/nar/30.9.1911 ↗
61. FDA-Approved Oligonucleotide Therapies in 201710.1016/j.ymthe.2017.03.023 ↗
62. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma10.1016/j.canlet.2011.05.017 ↗
63. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-9210.1182/blood-2018-03-836601 ↗
64. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis10.1073/pnas.0806202105 ↗
65. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM10.1371/journal.pone.0002236 ↗
66. Silencing of the miR-17∼92 cluster family inhibits medulloblastoma progression10.1158/0008-5472.CAN-13-0927 ↗
67. Dysfunction of microRNA-32 regulates ubiquitin ligase FBXW7 in multiple myeloma disease10.2147/OTT.S105945 ↗
68. A cellular microRNA mediates antiviral defense in human cells10.1126/science.1108784 ↗
69. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β810.1038/onc.2010.465 ↗
70. miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway10.18632/oncotarget.3221 ↗
71. Cancer Statistics, 2021
72. Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer10.1038/cgt.2016.2 ↗
73. Up-regulation of miR-95-3p in hepatocellular carcinoma promotes tumorigenesis by targeting p21 expression10.1038/srep34034 ↗
74. KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p10.7150/ijbs.45999 ↗
75. Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process10.1371/journal.pone.0057882 ↗
76. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells10.1002/jcp.24669 ↗
77. MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis10.1038/ncomms8096 ↗
78. miR-125a-5p post-transcriptionally suppresses GALNT7 to inhibit proliferation and invasion in cervical cancer cells via the EGFR/PI3K/AKT pathway10.1186/s12935-020-01209-8 ↗
79. A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer10.1038/s41598-019-43100-1 ↗
80. Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin10.1158/0008-5472.CAN-11-0991 ↗
81. miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD410.1016/j.prp.2019.152603 ↗
82. Bone protection by inhibition of microRNA-18210.1038/s41467-018-06446-0 ↗
83. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP110.1016/j.gene.2013.12.043 ↗
84. Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies10.3109/10428194.2012.693178 ↗
85. miR-208a-3p Suppresses Osteoblast Differentiation and Inhibits Bone Formation by Targeting ACVR110.1016/j.omtn.2017.11.009 ↗
86. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure10.1161/CIRCULATIONAHA.111.030932 ↗
87. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway10.1080/15476286.2015.1017205 ↗
88. Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma
89. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma10.18632/oncotarget.820 ↗
90. Oncogenic role of microRNA-20a in human multiple myeloma10.2147/OTT.S143612 ↗
91. Targeting miR-155-5p and miR-221-3p by peptide nucleic acids induces caspase-3 activation and apoptosis in temozolomide-resistant T98G glioma cells
92. Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia10.1007/s12288-016-0694-7 ↗
93. The interferon response circuit: induction and suppression by pathogenic viruses10.1016/j.virol.2005.09.024 ↗
94. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon10.1016/0092-8674(90)90374-N ↗
95. The multiple faces of proteinkinase R in antiviral defense10.4161/viru.23134 ↗
96. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p2710.1182/blood-2009-11-254656 ↗
97. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation10.1038/sj.emboj.7601790 ↗
98. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival10.1158/0008-5472.CAN-07-6754 ↗
99. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo10.1038/leu.2015.124 ↗
100. IRF4 addiction in multiple myeloma10.1038/nature07064 ↗